Journal
Cancer Research Communications
Publication Date
7-1-2024
Volume
4
Issue
7
First Page
1726
Last Page
1737
Document Type
Open Access Publication
DOI
10.1158/2767-9764.CRC-24-0252
Rights and Permissions
Gonzalez-Kozlova E, Huang HH, Jagede OA, Tuballes K, Del Valle DM, Kelly G, Patel M, Xie H, Harris J, Argueta K, Nie K, Barcessat V, Moravec R, Altreuter J, Duose DY, Kahl BS, Ansell SM, Yu J, Cerami E, Lindsay JR, Wistuba II, Kim-Schulze S, Diefenbach CS, Gnjatic S. Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma. Cancer Res Commun. 2024 Jul 1;4(7):1726-1737. doi: 10.1158/2767-9764.CRC-24-0252 This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license. ©2024 The Authors; Published by the American Association for Cancer Research
Recommended Citation
Gonzalez-Kozlova, Edgar; Kahl, Brad S; and et al., "Tumor-immune signatures of treatment resistance to brentuximab vedotin with ipilimumab and/or nivolumab in Hodgkin lymphoma." Cancer Research Communications. 4, 7. 1726 - 1737. (2024).
https://digitalcommons.wustl.edu/oa_4/3946
Additional Links
Supplemental material is available for this article at publisher site.
